Table 4 Medication use during the course of the disease (percentage)
From: Juvenile Psoriatic Arthritis (JPsA): juvenile arthritis with psoriasis?
ERA N=16 | Persistent oligoarticular course N=44 | Extended oligoarticular course N=21 | RF-polyarticular N=34 | Polyarticular course N=55 | Total cohort N=115 | P value | |
|---|---|---|---|---|---|---|---|
Methotrexate | 4 (25.0) | 8 (18.2) | 10(47.6) | 13(38.2) | 23 (41.8) | 35 (22.6) | 0.03 |
Anti-TNF agent | 2 (12.5) | 1 (2.3) | 6(28.5) | 2(5.9) | 7* (12.7) | 10 (8.7) | 0.16 |
Etanercept | 1 (6.2) | 1 (2.3) | 5(23.8) | 2(5.9) | 7 (12.7) | 9 (7.8) | 0.15 |
Infliximab | 1 (6.2) | 0 (0) | 1(4.7) | 0(0) | 1 (1.8) | 2 (1.7) | 0.26 |
Any DMARD | 4 (25.0) | 10 (22.7) | 11(52.4) | 14(41.2) | 25 (45.4) | 39 (33.9) | 0.04 |
Prednisone | 2 (12.5) | 1 (2.3) | 4(19) | 3(8.8) | 7 (12.7) | 10 (8.7) | 0.15 |